- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05642364
Virtual Reality in Hemodialysis to Improve Psychological Well-being
Positive Psychological Intervention Delivered Using Virtual Reality in Hemodialysis Patients With Comorbid Depression: Randomized Controlled Trial Assessing Feasibility and Efficacy Testing
The long-term goal is to create behavioral health technologies to advance the science that leverages state-of-the-art technology to delivery psychotherapeutic treatment to individuals on hemodialysis (HD) to improve their emotional well-being, quality of life, and overall health. The objective in this small R01 study is to design a virtual reality (VR) platform, that fully immerses users into a fictitious lifelike environment, to deliver an evidence-based positive psychological intervention and to test whether it improves the emotional well-being of individuals on HD with comorbid depression. In this proposed 2-arm randomized controlled trial, the investigators hypothesize that delivery of psychotherapy in individuals on HD using a VR environment will prove feasible and will result in significant improvements in depressive symptoms, quality of life, and treatment adherence, along with reduced rates of hospitalization when compared to an active control condition-all while serving as a cost-effective and far-reaching platform for expansive dissemination.
The Specific Aims are:
Aim #1: To develop VR software to immersively deliver the skills taught in a 5-week evidence-based positive psychological intervention in individuals on HD to improve their emotional well-being.
Aim #2: To evaluate the acceptability and feasibility of a 5-week positive psychological intervention, delivered using a VR platform through consideration of rates of recruitment, refusal, retention, (non)compliance, and adherence.
Aim #3: To test initial efficacy of the VR-based psychotherapeutic intervention, compared to a control arm, on outcomes of depression, psychological well-being, quality of life, treatment adherence, HD sessions missed, and hospitalizations in HD patients.
Knowledge gained from completion of the proposed research will result in the first VR software application to deliver psychotherapy to individuals on HD, while simultaneously allowing them to leave the confines of the clinic and virtually travel to distant regions of the world. This new therapeutic approach can be used to successfully address the added burden of psychological distress experienced by individuals on HD, with the potential to positively impact their quality of life, engagement in healthful behaviors, and overall healthy longevity. And, these findings will yield data essential for a fully-powered trial testing important health outcomes and biomarkers in individuals on HD.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Rosalba Hernandez, PhD
- Phone Number: 3129965706
- Email: rherna17@uic.edu
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 1) HD patient with at least three months since treatment initiation
- 2) Beck Depression Inventory-II (BDI-II) score ≥11
- 3) age 21 or older
- 4) visual and audio acuity to immerse in our VR world
- (5) fluent in English or Spanish
Exclusion Criteria:
- 1) unavailable for study period
- 2) prevalent cognitive impairment denoting dementia
- 3) physical limitation restricting use of a head-mounted display
- 4) history of epilepsy, seizures, or vertigo.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Virtual Reality Treatment
VR-delivered JovialityTM Sessions: Treatment Group.
Participants will interact with a newly-developed VR environment over a 5-week period, during regularly scheduled maintenance HD treatment.
Each week, enrollees will be introduced to a new skill, all taught in distinctive VR environments-with immersive sessions lasting no more than 30 minutes.
The investigators' 5-week positive psychological intervention covers the following topics: (1) noticing positive events, (2) amplifying positive events, (3) gratitude, (4) behavioral activation, (5) mindfulness/meditation, (6) positive reappraisal, (7) personal strengths, and (8) acts of kindness.
Delivery of intervention content will require VR immersion for no more than 30 minutes during each HD session (i.e., 30-min.
sessions thrice weekly).
VR immersion will only occur chairside when patients are already sedentary and in a seated position during regularly scheduled HD treatment, thus avoiding increased sedentarism.
|
5-week positive psychological intervention delivered using 3D virtual reality software that is immersive and uses a head-mounted display
Other Names:
|
Active Comparator: Inert Virtual Reality
Participants randomized to the control arm will receive a rigorous placebo following clinical trial guidelines of VR-CORE, which consists of 2-dimensional (2D) non-immersive visual content displayed on the head-mounted display.
Footage of wildlife and nature-based settings are visually displayed as part of the 'Sham' VR with inert music that does not promote high levels of relaxation or distraction.
The 'Sham' VR experience has very passive features, such that it mimics viewing content on a large flatscreen television.
Passive viewing during the 'Sham' VR experience rotates content using twenty different videos and has a duration time that is matched to that of JovialityTM over the 5-week intervention period.
|
Participants randomized to the control arm will receive a rigorous placebo following clinical trial guidelines of VR-CORE, which consists of 2-dimensional (2D) non-immersive visual content displayed on the HMD.
Footage of wildlife and nature-based settings are visually displayed as part of the Sham VR with inert music that does not promote high levels of relaxation or distraction.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility: Recruitment
Time Frame: Through study completion, an average 6 months.
|
Proportion of potential enrollees who were approached for recruitment.
|
Through study completion, an average 6 months.
|
Feasibility: Retention rates
Time Frame: Post-intervention at 6-months
|
Defined as completing all post-intervention assessments, categorized as a binary outcome Target: ≥75%
|
Post-intervention at 6-months
|
Feasibility: Non-Compliance/Adherence
Time Frame: Immediately post-intervention at 5-weeks
|
Measured by the proportion of the intervention completed (e.g., number of virtual reality environments viewed out of the total possible available across skill lessons in the intervention).
Target: ≥75%
|
Immediately post-intervention at 5-weeks
|
Feasibility: Refusal rates
Time Frame: Before enrollment
|
Proportion of potential enrollees who were approached for recruitment but decided not to enroll.
|
Before enrollment
|
Acceptability as assessed by whether a participant would recommend the JovialityTM software
Time Frame: Immediately post-intervention at 5-weeks
|
Acceptability as measured by whether a participant would recommend JovialityTM to other HD patients (0 definitely not, to 10 definitely yes).
Target: ≥8.0
|
Immediately post-intervention at 5-weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Depressive symptoms
Time Frame: Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention)
|
Depressive symptomatology will be assessed using the Beck Depression Inventory-II.
Scores range from 1 to 40 where a higher score indicates worse symptoms of depression.
|
Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention)
|
Kidney Disease and Quality of Life
Time Frame: Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention)
|
Kidney Disease and Quality of Life (KDQOL-SF™).
The scoring procedure first transforms the raw precoded numeric values of items to a 0-100 possible range, with higher transformed scores reflecting better quality of life.
|
Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention)
|
Number of missed hemodialysis treatment sessions
Time Frame: Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention)
|
Research staff will extract information from patient medical records to record the number of missed hemodialysis treatment sessions
|
Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention)
|
Emergency department visits and/or hospitalizations
Time Frame: Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention)
|
Research staff will extract information from patient medical records to record the number of emergency department visits and days of hospitalizations.
|
Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention)
|
Patient-Reported Outcomes Measurement Information System (PROMIS) computer adaptive test for depressive symptoms
Time Frame: Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention)
|
The Patient-Reported Outcomes Measurement Information System (PROMIS) computer adaptive test for depressive symptoms (range values: 28- 140) will serve as an additional measure to triangulate findings of the Beck Depression Inventory-II. A higher PROMIS T-score represents more of the concept being measured. |
Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention)
|
Patient-Reported Outcomes Measurement Information System (PROMIS) for anxiety
Time Frame: Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention)
|
The PROMIS adaptive measures for anxiety (range values: 29-145) will be used.
A higher PROMIS T-score represents more of the concept being measured.
|
Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention)
|
Patient-Reported Outcomes Measurement Information System (PROMIS) for perceived stress
Time Frame: Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention)
|
The PROMIS adaptive measures for perceived stress (range values: 29-145) will be used. A higher PROMIS T-score represents more of the concept being measured. |
Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention)
|
Patient-Reported Outcomes Measurement Information System (PROMIS) for life satisfaction
Time Frame: Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention)
|
The PROMIS adaptive measures for life satisfaction (range values: 10-60) will be used.
A higher PROMIS T-score represents more of the concept being measured.
|
Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention)
|
Patient-Reported Outcomes Measurement Information System (PROMIS) for positive affect
Time Frame: Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention)
|
The PROMIS adaptive measures for positive affect (range values: 34-170) will be used. A higher PROMIS T-score represents more of the concept being measured. |
Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention)
|
Patient-Reported Outcomes Measurement Information System (PROMIS) for life meaning and purpose
Time Frame: Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention)
|
The PROMIS adaptive measures for life meaning and purpose (range values 4-60) will be used.
A higher PROMIS T-score represents more of the concept being measured.
|
Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention)
|
Patient-Reported Outcomes Measurement Information System (PROMIS) for self-efficacy for managing emotions in the context of a chronic condition
Time Frame: Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention)
|
The PROMIS adaptive measures for self-efficacy for managing emotions in the context of a chronic condition (range values: 25-125) will be used.
A higher PROMIS T-score represents more of the concept being measured.
|
Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention)
|
Psychological well-being measured with the 7-item State Optimism Measure
Time Frame: Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention)
|
Additional measures of psychological well-being will include the optimism using the 7-item State Optimism Measure.
Scoring is mean score of items 1-7 with a higher score indicating greater state optimism.
|
Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention)
|
Psychological well-being measured with the Emotional Vitality Measure
Time Frame: Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention)
|
Additional measures of psychological well-being will also include emotional vitality (range values 0-110), as measured using select items of the General Well-being Schedule.
There are three proposed cut-points: total scores of 0-60 reflect "severe distress", 61-72 "moderate distress" and 73-110 "positive well-being"
|
Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention)
|
Psychological well-being measured with the Flourishing Index
Time Frame: Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention)
|
The "Flourish" measure is obtained by summing the scores from each of the first five domains. The "Secure Flourish" measure is obtained by summing the scores from all six domains including the financial and material stability domain. Each of the questions is assessed on a scale of 0-10. The secure flourishing index score is obtained by summing the scores from the twelve questions in all six domains and results in a score from 0 - 120. Often, for purposes of interpretation, the flourishing and secure flourishing scores are reported as averages of the questions (rather than sums) so that all scores are on a scale of 0-10. |
Baseline, immediately post-intervention (5-weeks) and at follow-up (3- and 6-months post-intervention)
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Rosalba Hernandez, PhD, University of Illinois Chicago
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19190
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depressive Symptoms
-
Finnish Institute for Health and WelfareUniversity of Helsinki; Tampere University; University of Eastern Finland; Strategic...RecruitingMajor Depressive Disorder | Depressive Symptoms Mild to Moderate in SeverityFinland
-
Julia EderNot yet recruitingDepressive Disorder | Depression | Depressive Symptoms | Major Depressive Disorder | Depressive EpisodeGermany
-
Medical Research CouncilKU LeuvenCompletedDepressive Symptoms | Major Depressive DisorderAustralia
-
Massachusetts General HospitalCompletedMajor Depressive DisorderUnited States, China
-
Dr. Nazanin AlaviCompletedDepression | Depressive Symptoms | Major Depressive DisorderCanada
-
Linkoeping UniversityCompletedMajor Depressive DisorderSweden
-
The University of Texas Health Science Center at...TerminatedDepression | Major Depressive DisorderUnited States
-
Santa Casa Medical SchoolFaculdade de Ciências Médicas da Santa Casa de São PauloUnknownDepressive SymptomsBrazil
-
State University of New York at BuffaloCompletedDepressive Symptoms | Major Depressive Disorder, Recurrent, in RemissionUnited States
-
University of TorontoKaiser Permanente; University of Colorado, BoulderCompletedDepressive Symptoms | Major Depressive Disorder, Recurrent, in RemissionUnited States
Clinical Trials on Joviality(TM)
-
Washington University School of MedicineNational Cancer Institute (NCI); National Institutes of Health (NIH); Atrium...CompletedVentral Hernia | AdhesionsUnited States
-
NephroSantNot yet recruitingKidney Transplant Failure and Rejection
-
University Hospital TuebingenTerminatedApnea of Prematurity | Continuous Positive Airway Pressure | CPAP
-
Boston UniversityNational Institute of Dental and Craniofacial Research (NIDCR)Not yet recruitingHIV Infections
-
Ivoclar Vivadent AGNot yet recruitingClass I or II Cavities in Premolars or Molars
-
Tufts UniversityBioElectronics CorporationTerminatedPostoperative Edema and PainUnited States
-
BioTech Tools S.A.Completed
-
Zimmer BiometActive, not recruitingOsteoarthritis | Rheumatoid Arthritis | Avascular Necrosis | Post-traumatic Arthritis | Revision Total Shoulder Arthroplasty | Ununited Humeral Head Fracture | Irreducible 3-and 4-part Proximal Humeral Fractures | Gross Rotator Cuff DeficiencyUnited States, United Kingdom
-
BioStream Technologies, LLCCompletedAutism Spectrum DisorderUnited States
-
RWTH Aachen UniversityUniversity of ChicagoCompleted